We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-1.62%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.99B
AUM Growth
-$546M
Cap. Flow
-$71.8M
Cap. Flow %
-2.4%
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$131M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$75.7M
3
IGMS
IGM Biosciences
IGMS
+$63.5M
4
ALLK
Allakos
ALLK
+$51.3M
5
NVRO
NEVRO CORP.
NVRO
+$48.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$405M
2
EHTH icon
eHealth
EHTH
+$76.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$62.6M
4
ELV icon
Elevance Health
ELV
+$51.8M
5
UNH icon
UnitedHealth
UNH
+$34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Miscellaneous 0.93%
3 Energy 0.01%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
$35.4M 1.18%
14,616,560
+661,766
+5% +$1.76M
CNC icon
27
Centene
CNC
$32B
$35.1M 1.17%
810,498
+119,628
+17% +$5.83M
EIDX
28
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$33.2M 1.11%
923,003
+44,600
+5% +$1.74M
REPL icon
29
Replimune Group
REPL
$1.46B
$30.8M 1.03%
2,213,417
+16,414
+0.7% +$201K
XNCR icon
30
Xencor
XNCR
$1.94B
$29.7M 0.99%
879,627
-733,171
-45% -$29.3M
XERS icon
31
Xeris Biopharma Holdings
XERS
$1.55B
$29.5M 0.99%
3,000,641
– –
HCA icon
32
HCA Healthcare
HCA
$90.5B
$28.4M 0.95%
+235,500
New +$30.4M
TCRR
33
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$26.9M 0.9%
1,790,288
-8,928
-0.5% -$139K
GRTS
34
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$26.8M 0.9%
3,104,494
-111,500
-3% -$1.13M
AKRO
35
DELISTED
Akero Therapeutics
AKRO
$26.5M 0.89%
1,164,402
-4,400
-0.4% -$102K
SRRK icon
36
Scholar Rock
SRRK
$7.04B
$25.6M 0.86%
2,857,389
-63,000
-2% -$753K
LIVN icon
37
LivaNova
LIVN
$4.43B
$25.3M 0.85%
342,987
-81,000
-19% -$6.24M
GMAB icon
38
Genmab
GMAB
$20.4B
$25.3M 0.85%
+1,248,600
New +$24.6M
JAZZ icon
39
Jazz Pharmaceuticals
JAZZ
$15.9B
$24M 0.8%
187,599
+19,212
+11% +$2.58M
PRNB
40
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$22.3M 0.75%
790,006
+545,906
+224% +$20M
STOK icon
41
Stoke Therapeutics
STOK
$2.04B
$21.9M 0.73%
1,017,478
-4,330
-0.4% -$121K
AXNX
42
DELISTED
Axonics, Inc. Common Stock
AXNX
$21.8M 0.73%
809,700
-3,800
-0.5% -$132K
ANAB icon
43
AnaptysBio
ANAB
$1.67B
$21.4M 0.72%
612,558
+2,900
+0.5% +$138K
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$20.1M 0.67%
773,571
+32,900
+4% +$1.1M
CBAY
45
DELISTED
Cymabay Therapeutics
CBAY
$16M 0.53%
3,115,865
-22,500
-0.7% -$136K
HOOK
46
DELISTED
HOOKIPA Pharma
HOOK
$14.2M 0.48%
189,772
+584
+0.3% +$43.1K
CLVS
47
DELISTED
Clovis Oncology, Inc.
CLVS
$14.2M 0.47%
3,607,800
+145,500
+4% +$1.18M
BCEL
48
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$13.9M 0.47%
1,139,106
-1,200
-0.1% -$18.2K
ADPT icon
49
Adaptive Biotechnologies
ADPT
$4.02B
$13.1M 0.44%
424,000
-1,000
-0.2% -$40.8K
STXS icon
50
Stereotaxis
STXS
$145M
$11.5M 0.39%
+3,285,000
New +$12.6M
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2019 Portfolio in Review

As of Q3 2019, Redmile Group held 90 positions worth $2.99B, down 15% from $3.53B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q3 2019 filing shows 10 new, 29 increased, 22 reduced and 16 closed positions. Its largest new stake was Alexion Pharmaceuticals: 1,162,200 shares worth $114M. The largest sale was Array Biopharma Inc, an estimated $405M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Energy.

  • Redmile Group's largest Q3 2019 buy was Alexion Pharmaceuticals: 1,162,200 shares worth $114M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019, an estimated $75.7M increase.
  • Redmile Group's biggest Q3 2019 reduction was UnitedHealth, cutting an estimated $34M.
  • Redmile Group fully exited Array Biopharma Inc in Q3 2019, selling an estimated $405M.
  • Redmile Group's ten largest holdings make up 49% of its $2.99B portfolio in Q3 2019.
  • Redmile Group opened 10 new positions and closed 16 in Q3 2019.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $2.99B.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.